A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1179 participants.

Also called NCT01095653

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,179 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01095653
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, India, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01095653. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2017-02-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Metformin
Intervention (Drug)
Dapagliflozin Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Astra Zeneca, Bristol-Myers Squibb (class: other)

Record details

Record id
cardio:ct-nct01095653
Content hash
51700e32ad9436e44f75b1bc16d124b29967991add06f7d25049bf36984887dc